<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00720135</url>
  </required_header>
  <id_info>
    <org_study_id>03131</org_study_id>
    <secondary_id>NCI-2010-01228</secondary_id>
    <secondary_id>CDR0000598679</secondary_id>
    <secondary_id>P50CA107399</secondary_id>
    <nct_id>NCT00720135</nct_id>
  </id_info>
  <brief_title>Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase I Study of De-Immunized DI-Leu16-IL2 Immunocytokine in Patients With B-Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as fusion protein cytokine therapy, may stimulate the&#xD;
      immune system in different ways and stop cancer cells from growing. Monoclonal antibodies,&#xD;
      such as rituximab, can block cancer growth in different ways. Some block the ability of&#xD;
      cancer cells to grow and spread. Others find cancer cells and help kill them or carry&#xD;
      cancer-killing substances to them. Giving fusion protein cytokine therapy together with&#xD;
      rituximab may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of fusion protein&#xD;
      cytokine therapy when given after rituximab in treating patients with B-cell non-Hodgkin&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD) of DI-Leu16-IL2 (DI-Leu16-IL2&#xD;
      immunocytokine) following peripheral blood B cell depletion with rituximab in patients with&#xD;
      B-cell NHL.&#xD;
&#xD;
      II. To investigate the optimal biological dose (OBD) of DI-Leu16-IL2 following peripheral&#xD;
      blood B cell depletion with rituximab in patients with B-cell NHL, which may differ from the&#xD;
      MTD.&#xD;
&#xD;
      III. To describe the toxicities associated with the proposed DI-Leu16-IL2 regimen.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the immunogenicity as measured by the induction of DI-Leu16-IL2-specific&#xD;
      antibodies.&#xD;
&#xD;
      II. To evaluate the pharmacokinetics of DI-Leu16-IL2. III. To document any clinical responses&#xD;
      associated with the proposed therapy and survival endpoints of the enrolled patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of DI-Leu16-IL2 immunocytokine.&#xD;
&#xD;
      Patients receive DI-Leu16-IL2 immunocytokine IV over 4 hours on 4 consecutive Wednesdays.&#xD;
&#xD;
      Patients with detectable CD20-positive B-cells pretreatment also receive rituximab IV on 4&#xD;
      consecutive Tuesdays.&#xD;
&#xD;
      Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of DI-Leu16-IL2</measure>
    <time_frame>6 weeks post cycle 1 of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimal biologic dose of DI-Leu16-IL2</measure>
    <time_frame>6 weeks after final cycle of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicities associated with the DI-Leu16-IL2 regimen</measure>
    <time_frame>6 weeks after final cycle of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as a result of DI-Leu16-IL2 administration</measure>
    <time_frame>Within 2 weeks following a 4 week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of DI-Leu16-IL2 administration</measure>
    <time_frame>6 weeks after final cycle of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical responses and survival</measure>
    <time_frame>Within two weeks following completion of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Cutaneous B-cell Non-Hodgkin Lymphoma</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Intraocular Lymphoma</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Small Intestine Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Testicular Lymphoma</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive DI-Leu16-IL2 immunocytokine IV over 4 hours on 4 consecutive Wednesdays. Patients with detectable CD20-positive B-cells pretreatment also receive rituximab IV on 4 consecutive Tuesdays. Treatment repeats every 6-8 weeks for up to a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DI-Leu16-IL2 immunocytokine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>de-immunized anti-CD20-IL-2 immunocytokine DI-Leu16-IL-2</other_name>
    <other_name>DI-Leu16-IL-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 monoclonal antibody</other_name>
    <other_name>Mabthera</other_name>
    <other_name>MOAB IDEC-C2B8</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>enzyme-linked immunosorbent assay</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>ELISA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>RT-PCR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
          -  Patients with CD20-expressing B cell NHL that is relapsed or refractory to standard&#xD;
             therapy; CLL/SLL with peripheral blood leukemia/lymphoma cells and high-grade&#xD;
             lymphomas (i.e., lymphoblastic lymphoma/Burkitt lymphoma) are excluded&#xD;
&#xD;
          -  Patients must have received prior Rituxan&#xD;
&#xD;
          -  Measurable disease; in the absence of lymphadenopathy, splenomegaly with defects or&#xD;
             measurable extramedullary disease is acceptable; however, bone marrow involvement&#xD;
             alone will not be included in the study&#xD;
&#xD;
          -  Age &gt;=18 years and &lt;=65 physiologic years of age&#xD;
&#xD;
          -  KPS &gt;= 70%&#xD;
&#xD;
          -  Life expectancy &gt;= 12 weeks&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 mg/dl&#xD;
&#xD;
          -  Total WBC &gt;= 3000/ul or absolute neutrophil count (ANC) &gt;= 1000/ul&#xD;
&#xD;
          -  Lymphocyte count &gt;= 0.2 x 10^3/ul&#xD;
&#xD;
          -  Platelet count &gt;= 75,000/ul&#xD;
&#xD;
          -  Hematocrit &gt;= 25% or hemoglobin &gt;= 9 g/100 ml&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) =&lt; 2.5 x UNL&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) =&lt; 2.5 x UNL&#xD;
&#xD;
          -  Total bilirubin (TBili) &lt; 1.5 x UNL&#xD;
&#xD;
          -  Sodium, potassium, and phosphorus within normal limits&#xD;
&#xD;
          -  Chest x ray (CXR) within 4 weeks prior to Day 1 with no evidence of pulmonary&#xD;
             congestion, pleural effusions, pulmonary fibrosis, or significant emphysema; if&#xD;
             results are questionable, subjects would have additional lung function testing to&#xD;
             exclude clinically relevant restriction or obstruction; subjects must have an FEV-1&#xD;
             and DLCO of at least 65% and 50% of expected, respectively&#xD;
&#xD;
          -  Electrocardiogram (12-lead ECG)&#xD;
&#xD;
          -  Echocardiogram (or MUGA) with normal left ventricular function&#xD;
&#xD;
          -  Cardiac stress test (e.g., stress thallium scan, stress echocardiography) with normal&#xD;
             results if subject is suspected to have coronary artery disease&#xD;
&#xD;
          -  Fasting blood glucose (FBG) &lt; 160 and hemoglobin (Hgb) A1C &lt; 7% for subjects with&#xD;
             diabetes mellitus (DM) or borderline DM&#xD;
&#xD;
          -  Women of procreative potential must have negative pregnancy test within the 2-week&#xD;
             screening phase prior to Cycle 1, and all subjects of procreative potential must use&#xD;
             adequate birth control throughout the study; subjects of procreative potential are&#xD;
             defined as any fertile male, and any female who has experienced menarche and has not&#xD;
             undergone successful surgical sterilization (hysterectomy or bilateral oophorectomy)&#xD;
             or is not post-menopausal, defined as age-related amenorrhea &gt;= 12 months&#xD;
&#xD;
          -  Provide written informed consent prior to any screening procedures&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  Evidence of CNS lymphoma or lymphomatous meningitis&#xD;
&#xD;
          -  Prior treatment with IL-2&#xD;
&#xD;
          -  Type I hypersensitivity or anaphylactic reactions to murine proteins or to previous&#xD;
             infusion of rituximab&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
&#xD;
          -  An immediate need for palliative radiotherapy or systemic corticosteroid therapy&#xD;
&#xD;
          -  Known intercurrent infections (including hepatitis C virus [HCV] and HIV or other&#xD;
             conditions), or clinical evidence of these conditions&#xD;
&#xD;
          -  Actively infected with or chronic carriers of hepatitis B virus (HBV) as demonstrated&#xD;
             by positive hepatitis B core antibody (HbcHb) or hepatitis B surface antigen (HbsAg);&#xD;
             (subjects who are sero-positive only, i.e., surface antibody positive [HbsAg], are&#xD;
             permitted)&#xD;
&#xD;
          -  Other significant active infection&#xD;
&#xD;
          -  Major surgery, chemotherapy, investigational agent, or radiation within 30 days of Day&#xD;
             1&#xD;
&#xD;
          -  Uncontrolled hypertension (diastolic &gt;= 100 mmHg) or hypotension (systolic =&lt; 90 mmHg)&#xD;
&#xD;
          -  History of repeated and clinically relevant episodes of syncope or other paroxysmal,&#xD;
             ventricular, or other significant arrhythmias&#xD;
&#xD;
          -  On ECG: a marked baseline prolongation of QT/QTc interval (&gt; grade 2 QTc interval &gt;&#xD;
             470 milliseconds)&#xD;
&#xD;
          -  History of medically significant ascites requiring repetitive paracentesis&#xD;
&#xD;
          -  Previous diagnosis of Addison's disease&#xD;
&#xD;
          -  Previous diagnosis of autoimmune disease (exceptions: subjects with autoimmune&#xD;
             thyroiditis or vitiligo may be enrolled)&#xD;
&#xD;
          -  Organ transplant recipient&#xD;
&#xD;
          -  History of prior therapy or a serious, uncontrolled medical disorder that in the&#xD;
             investigator's opinion would impair participation in the study&#xD;
&#xD;
          -  Known hypersensitivity to Tween-80 or human immunoglobulin&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Patients with bulky lymph nodes (&gt;= 10cm) or marked splenomegaly (i.e., extending into&#xD;
             pelvis or crossing the midline)&#xD;
&#xD;
          -  Positive anti-DI-Leu16-IL2 antibody assay (where positive is defined as &gt; 10% of the&#xD;
             radiolabeled DI-Leu16-IL2 reactive with the subject's serum)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryotaro Nakamura</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>July 19, 2008</study_first_submitted>
  <study_first_submitted_qc>July 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2008</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Intraocular Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

